Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Rekindling cancer vaccines

Nature Biotechnology volume 34, pages 1019–1024 (2016)Cite this article

Subjects

An Erratum to this article was published on 07 December 2016

This article has been updated

Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Stimulatory and inhibitory factors in the cancer-immunity cycle.
Figure 2: Somatic mutation burden by cancer.

Change history

  • 02 November 2016

    In the version of this article initially published, on p.1024, middle column, the quote, “We have ipilimumab....” should have read, “We have tremelimumab....” The error has been corrected in the HTML and PDF versions of the article.

References

  1. Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

    Article  CAS  Google Scholar 

  2. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).

    Article  CAS  Google Scholar 

  3. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).

    Article  CAS  Google Scholar 

  4. Bouchie, A. & DeFrancesco, L. Nature Biotechnology's academic spinouts of 2015. Nat. Biotechnol. 34, 484–492 (2016).

    Article  CAS  Google Scholar 

  5. Le, D.T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382–389 (2013).

    Article  CAS  Google Scholar 

  6. Lutz, E.R., Kinkead, H., Jaffee, E.M. & Zheng, L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology 3, e962401 (2014).

    Article  Google Scholar 

  7. Garde, D. Aduro slips after trial patient comes down with a dangerous infection. Fierce Biotech, 24 November http://www.fiercebiotech.com/r-d/aduro-slips-after-trial-patient-comes-down-a-dangerous-infection (2015).

  8. Feuerstein, A. Advaxis cancer immunotherapy on hold due to patient death. The Street, 6 October https://www.thestreet.com/story/13314660/1/advaxis-cancer-immunotherapy-on-hold-due-to-patient-death.html (2015).

  9. Jochems, C. et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 63, 407–418 (2014).

    Article  CAS  Google Scholar 

  10. Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

    Article  Google Scholar 

  11. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

    Article  CAS  Google Scholar 

  12. Gulley, J.L. et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353–3362 (2005).

    Article  CAS  Google Scholar 

  13. Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 106, dju268 (2014).

    Article  Google Scholar 

  14. Sheikh, N. et al. Clonotypic diversification of intratumoral T cells following Sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 76, 3711–3718 (2016).

    Article  CAS  Google Scholar 

  15. Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra70 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Malorye Allison Branca is a freelance writer based in Acton, Massachusetts.,

    Malorye Allison Branca

Authors
  1. Malorye Allison Branca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Branca, M. Rekindling cancer vaccines. Nat Biotechnol 34, 1019–1024 (2016). https://doi.org/10.1038/nbt.3690

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3690

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology